Dr. Gasink is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Fl 3
Philadelphia, PA 19104Phone+1 215-349-8222Fax+1 215-615-0500
Education & Training
University of Pennsylvania Health SystemFellowship, Gastroenterology, 2001 - 2004- University of Pennsylvania Health SystemResidency, Internal Medicine, 1998 - 2001
University of Virginia School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2002 - 2018
Publications & Presentations
PubMed
- 5 citationsHLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients.Jean-Frédéric Colombel, María D Martín-Arranz, Brigitta Brinkman, Meijian Guan, Amy Hart
Inflammatory Bowel Diseases. 2024-11-04 - 7 citationsSafety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.Subrata Ghosh, Brian G Feagan, Elyssa Ott, Christopher Gasink, Bridget Godwin
Journal of Crohn's & Colitis. 2024-08-06 - 1 citationsEvolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.Jean-Frédéric Colombel, Bruce E Sands, Christopher Gasink, Benjamin Yeager, Omoniyi J Adedokun
Clinical Gastroenterology and Hepatology. 2024-01-01
Press Mentions
JnJ Tremfya Receives USFDA Approval for Adults with Moderately to Severely Active Ulcerative ColitisSeptember 11th, 2024- TREMFYA® (Guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson's Leadership in Inflammatory Bowel DiseaseSeptember 11th, 2024
- TREMFYA® (Guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson's Leadership in Inflammatory Bowel DiseaseSeptember 11th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
